The UK Competition Authority announces that several firms have been fined a total of over £35M for an anti-competitive arrangement in the supply of important National Health Service prescription anti-nausea tablets (Alliance Pharmaceuticals / Focus / Lexon)

KEYWORDS
Reference

UK Competition Authority, Alliance Pharmaceuticals / Focus / Lexon, Press release, 3 February 2022

On 3 February 2022, the UK Competition and Markets Authority (CMA) announced that – following an investigation into the conduct of several pharmaceutical firms – it had fined several firms a total of over £35 million for an anti-competitive arrangement in the supply of important National Health Service (NHS) prescription anti-nausea tablets. Whilst the CMA’s decision has so far only been announced, and it is therefore currently difficult to comment on the specifics of the investigation, the CMA’s press release

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.